Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Partially Double Blind, Placebo and Positive Controlled, 4 Way Crossover Study to Evaluate the Effect of Icosabutate (NST 4016) on the QT/QTc Interval in Healthy Subjects

NCT03577275 is registered in ClinicalTrials.gov with NorthSea Therapeutics B.V. as lead sponsor.

NCT NCT03577275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03577275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Partially Double Blind, Placebo and Positive Controlled, 4 Way Crossover Study to Evaluate the Effect of Icosabutate (NST 4016) on the QT/QTc Interval in Healthy Subjects
Lead sponsor
NorthSea Therapeutics B.V.
Phase
Phase 1
Overall status
Completed
Start date
June 15, 2018
Completion date
September 24, 2018
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias